Sign In
Buy GSK
$51.53
+0.0200 (+0.0388%)
At Close: Aug 04, 2026
Carat Group's Fred Hassan dives into what pharma companies to watch at 2025 ASCO Annual Meeting
12:23pm, Friday, 30'th May 2025
Fred Hassan, Carat Group chairman, joins 'Money Movers' to discuss pharma innovation in 2025 and what companies he's watching in the sector.
Is GSK PLC Sponsored ADR (GSK) Outperforming Other Medical Stocks This Year?
10:47am, Thursday, 29'th May 2025
Here is how GSK (GSK) and Amarin (AMRN) have performed compared to their sector so far this year.
Buy 5 High Dividend-Paying Giants to Stay Safe Amid Volatile Markets
08:11am, Thursday, 29'th May 2025
PM, CVS, ET, GSK and NWG, which offer high dividends and carry Zacks buy ranks, are strong picks for stability amid volatile market conditions of 2025.
Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday?
11:24am, Wednesday, 28'th May 2025
GSK plc GSK and Spero Therapeutics Inc SPRO on Wednesday announced that the pivotal phase 3 PIVOT-PO trial evaluating tebipenem HBr for complicated urinary tract infections (cUTIs) will stop early for
GSK, Spero to stop urinary tract infection drug trial due to early success
07:18am, Wednesday, 28'th May 2025
Spero Therapeutics and partner GSK said on Wednesday that an experimental drug for complicated urinary tract infections met the main goal of a late-stage trial and the companies will be stopping the t
If approved, tebipenem HBr could be the first oral carbapenem antibiotic for US patients with complicated urinary tract infections (cUTIs) An estimated 2.9 million cases of cUTIs are treated annually
GSK Gets CHMP Nod for Blenrep Combos in Multiple Myeloma
12:46pm, Monday, 26'th May 2025
GSK wins CHMP nod for Blenrep combos in relapsed or refractory multiple myeloma. A decision in the EU is expected in the third quarter of 2025.
FDA Approves GSK's Nucala for Expanded Use in COPD
07:21am, Friday, 23'rd May 2025
GSK's Nucala wins FDA nod for COPD with eosinophilic phenotype, marking its fifth indication and strengthening its respiratory portfolio.
Nucala (mepolizumab) approved by US FDA for use in adults with chronic obstructive pulmonary disease (COPD)
04:15pm, Thursday, 22'nd May 2025
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) as an add-on maintenance treatment for adult pat
GSK's asthma drug Nucala wins FDA's approval to treat 'smoker's lung'
02:13pm, Thursday, 22'nd May 2025
The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with a chronic lung disease commonly known as "smoker's lung", the company said on Thursda
Why GSK (GSK) is a Top Value Stock for the Long-Term
10:41am, Wednesday, 21'st May 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Gilead Sciences vs GSK: Which HIV Drugmaker is a Smarter Buy Now?
02:01pm, Tuesday, 20'th May 2025
Gilead Sciences, Inc. GILD and GSK GSK are pioneers in the human immunodeficiency virus (HIV) treatment space.
GSK or ACAD: Which Is the Better Value Stock Right Now?
12:41pm, Monday, 19'th May 2025
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of GSK (GSK) and Acadia Pharmaceuticals (ACAD). But which of these two stocks is more attra
GSK's Blood-Cancer Treatment Combinations Approved in Japan
02:41am, Monday, 19'th May 2025
The pharma company said it expects more approvals through the year following positive results from a Phase 3 trial.
GSK Inks $2B Deal With Boston Pharmaceuticals to Buy Liver Disease Drug
08:55am, Thursday, 15'th May 2025
Through the Boston Pharma deal, GSK aims to strengthen its pipeline, as some of its key products are nearing the end of their exclusivity period.
